Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06864936

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

The purpose of the research study is to explore new retinal imaging biomarkers of immune cell activity in MS during use of ublituximab (Briumvi) treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. This study will evaluate the efficacy of ublituximab to modulate MS pathology in a new manner. In order to assess this new biomarker, a specialized optical coherence tomography (OCT) scan will be performed at enrollment into the study and at 2 other timepoints throughout the study.

Subjects asked to take part in this study should have been diagnosed with relapsing multiple sclerosis (MS) and have recently been advised to start the medication ublituximab (Briumvi) or are currently on another medication for the treatment of their MS.

We plan to enroll 30 patients into this study. Fifteen (15) patients with Relapsing Remitting Multiple Sclerosis (RRMS) who are being initiated on B-cell depletion therapy by their treating physician at the University of Maryland Center for MS Treatment and Research will be offered enrollment into this study. Additionally, 15 age/sex matched patients with stable RRMS who are not undergoing any change in treatment and are not currently on B-cell depleting therapies will be enrolled as control subjects.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Multiple Sclerosis (MS) - Relapsing-remitting Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Nervous System Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Maryland, Baltimore

Baltimore, Maryland, 21201, United States

Location status: Recruiting

Location contact

Daniel Harrison, MD

CONTACT

[email protected]

410-328-5605

Daniel Harrison, MD

PRINCIPAL_INVESTIGATOR

Kerry Naunton, RN

CONTACT

[email protected]

410-328-1885

Osamah Saeedi, MD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For Ublituximab Group:

  • Ages 18-65
  • A diagnosis of relapsing MS (to include relapsing-remitting MS and active secondary progressive MS) according to 2017 Revised McDonald Criteria.
  • A recent referral for initiation of ublituximab for treatment of MS by the patient's treating physician.

For Comparison Group:

  • Ages 18 - 65
  • A diagnosis of relapsing-remitting MS according to 2017 Revised McDonald Criteria.
  • Currently on a stable dose of disease modifying treatment for MS with no plans for alternative therapy for the following year.

Exclusion criteria

For Ublituximab Group:

  • Known eye disease that may, in the opinion of the screening ophthalmologist, preclude proper analysis of data in this study. This includes, but is not limited to diabetic retinopathy, macular degeneration, and glaucoma.
  • Treatment with any B-cell depleting disease modifying therapy for MS (i.e. rituximab, ocrelizumab, ofatumumab, ublituximab, etc.) within the past 12 months.
  • History of life-threatening infusion reaction on ublituximab or prior anti-CD20 therapy
  • Any chronic or active infection that would preclude anti-CD20 therapy. This may include but is not limited to active hepatitis B virus (HBV) confirmed by positive results for Hepatitis B surface antigen (HBsAg) and anti-HBV tests, tuberculosis, and human immunodeficiency virus (HIV).
  • Receipt of any live of live-attenuated vaccines within 4 weeks prior to first ublituximab administration

For Comparison Group:

  • Known eye disease that may, in the opinion of the screening ophthalmologist, preclude proper analysis of data in this study. This includes, but is not limited to diabetic retinopathy, macular degeneration, and glaucoma.
  • Treatment with any B-cell depleting disease modifying therapy (i.e. rituximab, ocrelizumab, ofatumumab, ublituximab, etc.) within the past 12 months, or plans to initiate such a therapy in the following year.

Treatment and study plan

Ublituximab

Drug

ublituximab

Other disease modifying therapies

Other

Other disease modifying therapies for MS (not ublituximab)

Primary outcomes

  1. Evaluation of the effect of ublituximab on macular hyperreflective foci (HRF) in MS.

    Time frame: From enrollment until the last OCT at Months 6 and 12

    A change in the number of HRF seen on baseline compared to months 6 and 12 in the ublituximab grop compared to the comparison group

  2. Evaluation of the effect of ublituximab on inner limiting membrane (ILM) macrophage-like cells (MLC).

    Time frame: From enrollment until the last OCT at Months 6 and 12

    A change in the number of MLCs seen from baseline to months 6 and 12 in the ublituximab group compared to the comparison group.

Study contacts

Contact information is provided by the study sponsor or research team.

Kerry Naunton, RN

CONTACT

[email protected]

410-328-1885

Sponsors and collaborators

Lead sponsor

University of Maryland, Baltimore

Other

Collaborators

  • TG Therapeutics, Inc.

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Mar 7, 2025
Registry last updated
May 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.